Application No. 10/659,705 Docket No.: 0112706.00123US2

Amendment dated November 13, 2008 Response to Office Action of May 13, 2008

AMENDMENTS TO THE CLAIMS

1-74. (Cancelled)

75. (New) A transgenic fish whose genome comprises a cMYC oncogene operably linked

to a RAG2 promoter, wherein the oncogene is expressed in lymphoid cells and induces T-cell

acute lymphoblastic leukemia.

76. (New) The transgenic fish of claim 75, wherein the oncogene is fused to a reporter

gene.

77. (New) The transgenic fish of claim 76, wherein the reporter gene is a fluorescent

protein gene.

78. (New) The transgenic fish of claim 77, wherein the fluorescent protein gene is GFP.

79. (New) The transgenic fish of claim 75, wherein the oncogene is fused to ER.

80. (New) The transgenic fish of claim 79, wherein the ER is tamoxifen-sensitive ER

 $(ER^{Tm}).$ 

81. (New) The transgenic fish of claim 75, wherein the transgenic fish is a transgenic

zebrafish.

82. (New) A method of screening test drugs or agents that suppress oncogene-induced

leukemia, comprising:

contacting or otherwise exposing a transgenic fish to a test drug or agent, wherein the

transgenic fish has a genome that comprises a mouse cMYC oncogene operably linked to a

RAG2 promoter, and wherein expression of the oncogene induces T-cell acute lymphoblastic

leukemia;

-4-

Application No. 10/659,705 Docket No.: 0112706.00123US2 Amendment dated November 13, 2008

Response to Office Action of May 13, 2008

comparing the leukemia in said transgenic fish after contact or exposure to said test

drug or agent relative to the leukemia of said fish prior to contact or exposure with said test

drug or agent;

wherein suppression of the leukemia in said transgenic fish after contact or exposure

to said test drug or agent relative to the leukemia of said fish prior to contact or exposure

with said test drug or agent is indicative of a test drug or agent that suppresses oncogene-

induced leukemia.

83. (New) The method of claim 82, wherein the comparison step comprises measuring

the rate of onset of tumor formation resulting from oncogene-induced leukemia.

84. (New) The method of claim 82, wherein the comparison step comprises measuring

the amount or size of tumors resulting from oncogene-induced leukemia.

85. (New) The method of claim 82, wherein the test drug or agent is antisense DNA,

antisense RNA, or small interfering RNA.

86. (New) The method of claim 82, wherein the transgenic fish is a transgenic fish

embryo.

87. (New) The method of claim 82, wherein the transgenic fish is a transgenic zebrafish.

88. (New) The method of claim 86, wherein the transgenic fish embryo is a transgenic

zebrafish embryo.

- 5 -